|Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study|
M Zander, S Madsbad, JL Madsen, JJ Holst
The Lancet 359 (9309), 824-830, 2002
|Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients|
MB Toft-Nielsen, MB Damholt, S Madsbad, LM Hilsted, TE Hughes, ...
The Journal of Clinical Endocrinology & Metabolism 86 (8), 3717-3723, 2001
|Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients|
T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst
Diabetes 50 (3), 609-613, 2001
|Angiotensin-receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy|
AH Barnett, SC Bain, P Bouter, B Karlberg, S Madsbad, J Jervell, ...
New England Journal of Medicine 351 (19), 1952-1961, 2004
|The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects|
LL Kjems, JJ Holst, A Vølund, S Madsbad
Diabetes 52 (2), 380-386, 2003
|Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of …|
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, JP Courrèges, ...
Diabetes care 30 (6), 1608-1610, 2007
|Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus|
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, AG Juul, JJ Holst
The Journal of Clinical Endocrinology & Metabolism 88 (6), 2706-2713, 2003
|Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients|
T Vilsbøll, T Krarup, S Madsbad, J Holst
Diabetologia 45 (8), 1111-1119, 2002
|Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects|
T Vilsbøll, T Krarup, S Madsbad, JJ Holst
Regulatory peptides 114 (2-3), 115-121, 2003
|Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.|
C Orskov, J Jeppesen, S Madsbad, JJ Holst
The Journal of clinical investigation 87 (2), 415-423, 1991
|Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide …|
S Madsbad, O Schmitz, J Ranstam, G Jakobsen, DR Matthews
Diabetes care 27 (6), 1335-1342, 2004
|Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.|
MB Toft-Nielsen, S Madsbad, JJ Holst
Diabetes care 22 (7), 1137-1143, 1999
|Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?|
FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ...
Diabetes 56 (8), 1951-1959, 2007
|Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy|
N Engl J Med 351, 1952-1961, 2004
|Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study|
J Jeppesen, TW Hansen, S Rasmussen, H Ibsen, C Torp-Pedersen, ...
Journal of the American College of Cardiology 49 (21), 2112-2119, 2007
|Low birthweight is associated with specific changes in muscle insulin-signalling protein expression|
SE Ozanne, CB Jensen, KJ Tingey, H Storgaard, S Madsbad, AA Vaag
Diabetologia 48 (3), 547-552, 2005
|Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with …|
PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ...
Diabetologia 52 (2), 199-207, 2009
|Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects|
SH Jacobsen, SC Olesen, C Dirksen, NB Jørgensen, KN Bojsen-Møller, ...
Obesity surgery 22 (7), 1084-1096, 2012
|3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial|
CW Le Roux, A Astrup, K Fujioka, F Greenway, DCW Lau, L Van Gaal, ...
The Lancet 389 (10077), 1399-1409, 2017
|Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes|
NB Jørgensen, C Dirksen, KN Bojsen-Møller, SH Jacobsen, D Worm, ...
Diabetes 62 (9), 3044-3052, 2013